Sensitivity analysis examining alternate scenarios
| Male | Female | |||||||
|---|---|---|---|---|---|---|---|---|
| Mean lifespan gain (months) | Proportion not benefitting (%) | Proportion that benefits (%) | Mean lifespan gain for those benefitting (months) | Mean lifespan gain (months) | Proportion not benefitting (%) | Proportion that benefits (%) | Mean lifespan gain for those benefitting (months) | |
| 15% cardiovascular mortality | ||||||||
| Hazard reduction 0.2 | 3.0 | 97.1 | 2.9 | 103.4 | 2.9 | 97.1 | 2.9 | 97.4 |
| Hazard reduction 0.3 | 4.6 | 95.6 | 4.4 | 105.0 | 4.1 | 95.8 | 4.2 | 97.8 |
| Hazard reduction 0.4 | 6.1 | 94.1 | 5.9 | 103.7 | 5.9 | 94.1 | 5.9 | 100.6 |
| 20% cardiovascular mortality | ||||||||
| Hazard reduction 0.2 | 4.2 | 96.0 | 4.0 | 104.3 | 3.7 | 96.2 | 3.8 | 96.6 |
| Hazard reduction 0.3 | 6.1 | 94.0 | 6.0 | 102.3 | 5.9 | 94.1 | 5.9 | 99.5 |
| Hazard reduction 0.4 | 8.1 | 92.1 | 7.9 | 102.5 | 8.0 | 92.3 | 7.7 | 103.9 |
| 25% cardiovascular mortality | ||||||||
| Hazard reduction 0.2 | 5.2 | 94.9 | 5.1 | 101.1 | 4.7 | 95.2 | 4.8 | 97.4 |
| Hazard reduction 0.3 | 7.7 | 92.5 | 7.5 | 102.3 | 7.5 | 92.7 | 7.3 | 103.8 |
| Hazard reduction 0.4 | 10.5 | 90.1 | 9.9 | 106.4 | 10.5 | 90.3 | 9.7 | 108.2 |